Characteristicsa | All new users of palbociclib | New users of palbociclib-fulvestrant | New users of palbociclib-letrozole | All other new users of palbociclib | ||||
---|---|---|---|---|---|---|---|---|
N/Mean | %/SD | N/Mean | %/SD | N/Mean | %/SD | N/Mean | %/SD | |
Overall | 2445 | 100% | 566 | 100% | 1159 | 100% | 720 | 100% |
Total duration of follow-up of cohort (in years) | 1540 | 324 | 812 | 404 | ||||
Duration of follow-up (in years) | 0.63 | 0.53 | 0.57 | 0.43 | 0.70 | 0.58 | 0.56 | 0.50 |
Age at index date (in years) | 59.79 | 11.62 | 59.47 | 11.38 | 59.21 | 11.27 | 60.95 | 12.29 |
Sex | ||||||||
Male | 53 | 2.17 | < 10 | n/a | 14 | 1.21 | 30 | 4.17 |
Female | 2392 | 97.83 | 557 | 98.41 | 1145 | 98.79 | 690 | 95.83 |
Calendar year of index date | ||||||||
2015 | 791 | 32.35 | 99 | 17.49 | 456 | 39.34 | 236 | 32.78 |
2016 | 942 | 38.53 | 269 | 47.53 | 406 | 35.03 | 267 | 37.08 |
2017 | 712 | 29.12 | 198 | 34.98 | 297 | 25.63 | 217 | 30.14 |
Geographic region of residence | ||||||||
Midwest | 400 | 16.36 | 95 | 16.78 | 185 | 15.96 | 120 | 16.67 |
South | 581 | 23.76 | 159 | 28.09 | 288 | 24.85 | 134 | 18.61 |
Northeast | 696 | 28.47 | 166 | 29.33 | 340 | 29.34 | 190 | 26.39 |
West | 768 | 31.41 | 146 | 25.80 | 346 | 29.85 | 276 | 38.33 |
Secondary malignancy to any site (metastasis) | 2137 | 87.40 | 496 | 87.63 | 1044 | 90.08 | 597 | 82.92 |
Secondary malignancy to Lymph nodes of head, face, and neck metastasis | 690 | 28.22 | 154 | 27.20 | 356 | 30.72 | 180 | 25.00 |
Secondary malignancy to Respiratory and digestive system metastasis (includes liver metastasis) | 1058 | 43.27 | 257 | 45.41 | 490 | 42.28 | 311 | 43.19 |
Secondary malignancy to Metastasis to other specified sites | 2017 | 82.49 | 463 | 81.80 | 978 | 84.38 | 576 | 80.00 |
Deyo-Charlson comorbidity index (DCI) | 8.39 | 1.90 | 8.52 | 1.76 | 8.48 | 1.70 | 8.13 | 2.25 |
Advanced stage ER+/HER2- breast cancer | 2285 | 93.46 | 548 | 96.82 | 1083 | 93.44 | 654 | 90.83 |
Radiation therapy | 483 | 19.75 | 112 | 19.79 | 233 | 20.10 | 138 | 19.17 |
Chemotherapy | 472 | 19.30 | 100 | 17.67 | 218 | 18.81 | 154 | 21.39 |
CT related imaging | 602 | 24.62 | 139 | 24.56 | 333 | 28.73 | 130 | 18.06 |
Number of outpatient visits | 39.67 | 25.20 | 38.58 | 23.63 | 39.51 | 23.78 | 40.79 | 28.42 |
Aromatase inhibitor | 1527 | 62.45 | 326 | 57.60 | 815 | 70.32 | 386 | 53.61 |
HER2+ therapy | 72 | 2.94 | 15 | 2.65 | 35 | 3.02 | 22 | 3.06 |
Tamoxifen | 552 | 22.58 | 140 | 24.73 | 270 | 23.30 | 142 | 19.72 |
Fulvestrant | 621 | 25.40 | 238 | 42.05 | 112 | 9.66 | 271 | 37.64 |
Denosumab or pamidronate | 836 | 34.19 | 206 | 36.40 | 359 | 30.97 | 271 | 37.64 |
Everolimus | 150 | 6.13 | 40 | 7.07 | 52 | 4.49 | 58 | 8.06 |
Antihypertensives | 653 | 26.71 | 173 | 30.57 | 293 | 25.28 | 187 | 25.97 |
Corticosteroids | 606 | 24.79 | 148 | 26.15 | 308 | 26.57 | 150 | 20.83 |
Lipid lowering agent | 528 | 21.60 | 132 | 23.32 | 251 | 21.66 | 145 | 20.14 |
Pathologic fracture | 211 | 8.63 | 46 | 8.13 | 110 | 9.49 | 55 | 7.64 |
Pure hypercholesterolemia | 215 | 8.79 | 48 | 8.48 | 105 | 9.06 | 62 | 8.61 |